Safety and effectiveness of neoadjuvant pd-1 inhibitor (toripalimab) plus chemotherapy in stage ii-iii nsclc (lungmate 002): an open-label, single-arm, phase 2 trial

HIGHLIGHTS

• who: Xinsheng Zhu from the Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, No, Zhengmin Road, Shanghai, China have published the paper: Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial, in the Journal: (JOURNAL) of June/22,/2019
• what: The authors report the safety and effectiveness of neoadjuvant chemoimmunotherapy for patients with stage II-III NSCLC, including 12 patients with RD and 38 with PRD. The trial showed a comparable MPR of 55 . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.